Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Catalent Pharma Solutions has invested a further $5 million at the company’s Somerset, New Jersey, drug development center of excellence to expand its OptiMelt hot melt extrusion (HME) capabilities.

Catalent expands OptiMelt hot melt extrusion capabilities

As a technology, HME offers several advantages, including development of amorphous dispersions and controlled and modified drug delivery to enhance a drug’s bioavailability, as well as taste masking of bitter APIs. The investment will include the addition of a number of pieces of manufacturing and analytical equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

“The developmental challenges to overcome issues with drug solubility and bioavailability are well documented, and our OptiMelt HME technology is one of many potential solutions that Catalent has to offer,” commented Jonathan Arnold, President of Oral Drug Delivery at Catalent. “Our strategy is to work with drug innovators to optimize the formulation and delivery method of a drug, and HME enables us to develop more patient-centric dose forms, including controlled release.”

In 2018, Catalent announced an investment in the Somerset facility to create a new drug development center of excellence, which, alongside sites in San Diego, California and Nottingham, UK, offer formulation and development services focused on preclinical to clinical Phase IIb formulation, analytical, and manufacturing solutions for orally delivered small molecules.

Catalent’s 265,000-sq ft headquarters and development center in Somerset has a long track record of successfully developing, launching, and manufacturing many oral treatments for leading global innovators. The site houses state-of-the-art analytical labs, pilot and clinical scale equipment including hot melt extrusion and fluid-bed processing and has significant expertise in handling potent and US Drug Enforcement Administration (DEA) compounds for capsules, tablets, minitablets and multi-particulates.

Read More

Related news

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

15 Aug 2019

rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.

Read more 
rfxcel Awarded ISO 9001:2015 Certification

rfxcel Awarded ISO 9001:2015 Certification

14 Aug 2019

rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Using mobile phones to fight Alzheimer’s disease

Using mobile phones to fight Alzheimer’s disease

8 Aug 2019

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Read more 
Automation-compatible prepared culture media plate technology

Automation-compatible prepared culture media plate technology

6 Aug 2019

Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.

Read more 
Researchers develop 3D printed ingestible pill

Researchers develop 3D printed ingestible pill

4 Aug 2019

Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.

Read more 
Needle free: Erase wrinkles without injection

Needle free: Erase wrinkles without injection

15 Jul 2019

Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06

Read more 
Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Cyclolab Ltd strengthens its position in the market

Cyclolab Ltd strengthens its position in the market

1 Jul 2019

Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.

Read more